Medical Care
Global Lung Disease Therapeutics Market Research Report 2025
- May 05, 25
- ID: 226976
- Pages: 88
- Figures: 82
- Views: 39
The global market for Lung Disease Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Disease Therapeutics.
The Lung Disease Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lung Disease Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Disease Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Novartis
Mylan
Vertex Pharmaceuticals
F. Hoffman La Roche
Teva Pharmaceuticals
Cipla
Fibrogen
Liminal Biosciences
PharmAkea Therapeutics
IQVIA
Segment by Type
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Lung Diseases
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Disease Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Disease Therapeutics.
The Lung Disease Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lung Disease Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Disease Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Novartis
Mylan
Vertex Pharmaceuticals
F. Hoffman La Roche
Teva Pharmaceuticals
Cipla
Fibrogen
Liminal Biosciences
PharmAkea Therapeutics
IQVIA
Segment by Type
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Lung Diseases
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Disease Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Asthma
1.2.3 Chronic Obstructive Pulmonary Disease (COPD)
1.2.4 Lung Cancer
1.2.5 Other Lung Diseases
1.3 Market by Application
1.3.1 Global Lung Disease Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Disease Therapeutics Market Perspective (2020-2031)
2.2 Global Lung Disease Therapeutics Growth Trends by Region
2.2.1 Global Lung Disease Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lung Disease Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Lung Disease Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Lung Disease Therapeutics Market Dynamics
2.3.1 Lung Disease Therapeutics Industry Trends
2.3.2 Lung Disease Therapeutics Market Drivers
2.3.3 Lung Disease Therapeutics Market Challenges
2.3.4 Lung Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Disease Therapeutics Players by Revenue
3.1.1 Global Top Lung Disease Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Lung Disease Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Lung Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lung Disease Therapeutics Revenue
3.4 Global Lung Disease Therapeutics Market Concentration Ratio
3.4.1 Global Lung Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Disease Therapeutics Revenue in 2024
3.5 Global Key Players of Lung Disease Therapeutics Head office and Area Served
3.6 Global Key Players of Lung Disease Therapeutics, Product and Application
3.7 Global Key Players of Lung Disease Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Disease Therapeutics Breakdown Data by Type
4.1 Global Lung Disease Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Lung Disease Therapeutics Forecasted Market Size by Type (2026-2031)
5 Lung Disease Therapeutics Breakdown Data by Application
5.1 Global Lung Disease Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Lung Disease Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lung Disease Therapeutics Market Size (2020-2031)
6.2 North America Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lung Disease Therapeutics Market Size by Country (2020-2025)
6.4 North America Lung Disease Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Disease Therapeutics Market Size (2020-2031)
7.2 Europe Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lung Disease Therapeutics Market Size by Country (2020-2025)
7.4 Europe Lung Disease Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Disease Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Lung Disease Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lung Disease Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Lung Disease Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Disease Therapeutics Market Size (2020-2031)
9.2 Latin America Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lung Disease Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Lung Disease Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Disease Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lung Disease Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Lung Disease Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Lung Disease Therapeutics Introduction
11.1.4 GSK Revenue in Lung Disease Therapeutics Business (2020-2025)
11.1.5 GSK Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Lung Disease Therapeutics Introduction
11.2.4 AstraZeneca Revenue in Lung Disease Therapeutics Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Lung Disease Therapeutics Introduction
11.3.4 Boehringer Ingelheim Revenue in Lung Disease Therapeutics Business (2020-2025)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Lung Disease Therapeutics Introduction
11.4.4 Novartis Revenue in Lung Disease Therapeutics Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Lung Disease Therapeutics Introduction
11.5.4 Mylan Revenue in Lung Disease Therapeutics Business (2020-2025)
11.5.5 Mylan Recent Development
11.6 Vertex Pharmaceuticals
11.6.1 Vertex Pharmaceuticals Company Details
11.6.2 Vertex Pharmaceuticals Business Overview
11.6.3 Vertex Pharmaceuticals Lung Disease Therapeutics Introduction
11.6.4 Vertex Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025)
11.6.5 Vertex Pharmaceuticals Recent Development
11.7 F. Hoffman La Roche
11.7.1 F. Hoffman La Roche Company Details
11.7.2 F. Hoffman La Roche Business Overview
11.7.3 F. Hoffman La Roche Lung Disease Therapeutics Introduction
11.7.4 F. Hoffman La Roche Revenue in Lung Disease Therapeutics Business (2020-2025)
11.7.5 F. Hoffman La Roche Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Lung Disease Therapeutics Introduction
11.8.4 Teva Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025)
11.8.5 Teva Pharmaceuticals Recent Development
11.9 Cipla
11.9.1 Cipla Company Details
11.9.2 Cipla Business Overview
11.9.3 Cipla Lung Disease Therapeutics Introduction
11.9.4 Cipla Revenue in Lung Disease Therapeutics Business (2020-2025)
11.9.5 Cipla Recent Development
11.10 Fibrogen
11.10.1 Fibrogen Company Details
11.10.2 Fibrogen Business Overview
11.10.3 Fibrogen Lung Disease Therapeutics Introduction
11.10.4 Fibrogen Revenue in Lung Disease Therapeutics Business (2020-2025)
11.10.5 Fibrogen Recent Development
11.11 Liminal Biosciences
11.11.1 Liminal Biosciences Company Details
11.11.2 Liminal Biosciences Business Overview
11.11.3 Liminal Biosciences Lung Disease Therapeutics Introduction
11.11.4 Liminal Biosciences Revenue in Lung Disease Therapeutics Business (2020-2025)
11.11.5 Liminal Biosciences Recent Development
11.12 PharmAkea Therapeutics
11.12.1 PharmAkea Therapeutics Company Details
11.12.2 PharmAkea Therapeutics Business Overview
11.12.3 PharmAkea Therapeutics Lung Disease Therapeutics Introduction
11.12.4 PharmAkea Therapeutics Revenue in Lung Disease Therapeutics Business (2020-2025)
11.12.5 PharmAkea Therapeutics Recent Development
11.13 IQVIA
11.13.1 IQVIA Company Details
11.13.2 IQVIA Business Overview
11.13.3 IQVIA Lung Disease Therapeutics Introduction
11.13.4 IQVIA Revenue in Lung Disease Therapeutics Business (2020-2025)
11.13.5 IQVIA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Asthma
1.2.3 Chronic Obstructive Pulmonary Disease (COPD)
1.2.4 Lung Cancer
1.2.5 Other Lung Diseases
1.3 Market by Application
1.3.1 Global Lung Disease Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Disease Therapeutics Market Perspective (2020-2031)
2.2 Global Lung Disease Therapeutics Growth Trends by Region
2.2.1 Global Lung Disease Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lung Disease Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Lung Disease Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Lung Disease Therapeutics Market Dynamics
2.3.1 Lung Disease Therapeutics Industry Trends
2.3.2 Lung Disease Therapeutics Market Drivers
2.3.3 Lung Disease Therapeutics Market Challenges
2.3.4 Lung Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Disease Therapeutics Players by Revenue
3.1.1 Global Top Lung Disease Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Lung Disease Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Lung Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lung Disease Therapeutics Revenue
3.4 Global Lung Disease Therapeutics Market Concentration Ratio
3.4.1 Global Lung Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Disease Therapeutics Revenue in 2024
3.5 Global Key Players of Lung Disease Therapeutics Head office and Area Served
3.6 Global Key Players of Lung Disease Therapeutics, Product and Application
3.7 Global Key Players of Lung Disease Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Disease Therapeutics Breakdown Data by Type
4.1 Global Lung Disease Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Lung Disease Therapeutics Forecasted Market Size by Type (2026-2031)
5 Lung Disease Therapeutics Breakdown Data by Application
5.1 Global Lung Disease Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Lung Disease Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lung Disease Therapeutics Market Size (2020-2031)
6.2 North America Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lung Disease Therapeutics Market Size by Country (2020-2025)
6.4 North America Lung Disease Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Disease Therapeutics Market Size (2020-2031)
7.2 Europe Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lung Disease Therapeutics Market Size by Country (2020-2025)
7.4 Europe Lung Disease Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Disease Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Lung Disease Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lung Disease Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Lung Disease Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Disease Therapeutics Market Size (2020-2031)
9.2 Latin America Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lung Disease Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Lung Disease Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Disease Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Lung Disease Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lung Disease Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Lung Disease Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Lung Disease Therapeutics Introduction
11.1.4 GSK Revenue in Lung Disease Therapeutics Business (2020-2025)
11.1.5 GSK Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Lung Disease Therapeutics Introduction
11.2.4 AstraZeneca Revenue in Lung Disease Therapeutics Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Lung Disease Therapeutics Introduction
11.3.4 Boehringer Ingelheim Revenue in Lung Disease Therapeutics Business (2020-2025)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Lung Disease Therapeutics Introduction
11.4.4 Novartis Revenue in Lung Disease Therapeutics Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Lung Disease Therapeutics Introduction
11.5.4 Mylan Revenue in Lung Disease Therapeutics Business (2020-2025)
11.5.5 Mylan Recent Development
11.6 Vertex Pharmaceuticals
11.6.1 Vertex Pharmaceuticals Company Details
11.6.2 Vertex Pharmaceuticals Business Overview
11.6.3 Vertex Pharmaceuticals Lung Disease Therapeutics Introduction
11.6.4 Vertex Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025)
11.6.5 Vertex Pharmaceuticals Recent Development
11.7 F. Hoffman La Roche
11.7.1 F. Hoffman La Roche Company Details
11.7.2 F. Hoffman La Roche Business Overview
11.7.3 F. Hoffman La Roche Lung Disease Therapeutics Introduction
11.7.4 F. Hoffman La Roche Revenue in Lung Disease Therapeutics Business (2020-2025)
11.7.5 F. Hoffman La Roche Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Lung Disease Therapeutics Introduction
11.8.4 Teva Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025)
11.8.5 Teva Pharmaceuticals Recent Development
11.9 Cipla
11.9.1 Cipla Company Details
11.9.2 Cipla Business Overview
11.9.3 Cipla Lung Disease Therapeutics Introduction
11.9.4 Cipla Revenue in Lung Disease Therapeutics Business (2020-2025)
11.9.5 Cipla Recent Development
11.10 Fibrogen
11.10.1 Fibrogen Company Details
11.10.2 Fibrogen Business Overview
11.10.3 Fibrogen Lung Disease Therapeutics Introduction
11.10.4 Fibrogen Revenue in Lung Disease Therapeutics Business (2020-2025)
11.10.5 Fibrogen Recent Development
11.11 Liminal Biosciences
11.11.1 Liminal Biosciences Company Details
11.11.2 Liminal Biosciences Business Overview
11.11.3 Liminal Biosciences Lung Disease Therapeutics Introduction
11.11.4 Liminal Biosciences Revenue in Lung Disease Therapeutics Business (2020-2025)
11.11.5 Liminal Biosciences Recent Development
11.12 PharmAkea Therapeutics
11.12.1 PharmAkea Therapeutics Company Details
11.12.2 PharmAkea Therapeutics Business Overview
11.12.3 PharmAkea Therapeutics Lung Disease Therapeutics Introduction
11.12.4 PharmAkea Therapeutics Revenue in Lung Disease Therapeutics Business (2020-2025)
11.12.5 PharmAkea Therapeutics Recent Development
11.13 IQVIA
11.13.1 IQVIA Company Details
11.13.2 IQVIA Business Overview
11.13.3 IQVIA Lung Disease Therapeutics Introduction
11.13.4 IQVIA Revenue in Lung Disease Therapeutics Business (2020-2025)
11.13.5 IQVIA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Lung Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Asthma
Table 3. Key Players of Chronic Obstructive Pulmonary Disease (COPD)
Table 4. Key Players of Lung Cancer
Table 5. Key Players of Other Lung Diseases
Table 6. Global Lung Disease Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Lung Disease Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Lung Disease Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Lung Disease Therapeutics Market Share by Region (2020-2025)
Table 10. Global Lung Disease Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Lung Disease Therapeutics Market Share by Region (2026-2031)
Table 12. Lung Disease Therapeutics Market Trends
Table 13. Lung Disease Therapeutics Market Drivers
Table 14. Lung Disease Therapeutics Market Challenges
Table 15. Lung Disease Therapeutics Market Restraints
Table 16. Global Lung Disease Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Lung Disease Therapeutics Market Share by Players (2020-2025)
Table 18. Global Top Lung Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Disease Therapeutics as of 2024)
Table 19. Ranking of Global Top Lung Disease Therapeutics Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Lung Disease Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Lung Disease Therapeutics, Headquarters and Area Served
Table 22. Global Key Players of Lung Disease Therapeutics, Product and Application
Table 23. Global Key Players of Lung Disease Therapeutics, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lung Disease Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Lung Disease Therapeutics Revenue Market Share by Type (2020-2025)
Table 27. Global Lung Disease Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Lung Disease Therapeutics Revenue Market Share by Type (2026-2031)
Table 29. Global Lung Disease Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Lung Disease Therapeutics Revenue Market Share by Application (2020-2025)
Table 31. Global Lung Disease Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Lung Disease Therapeutics Revenue Market Share by Application (2026-2031)
Table 33. North America Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Lung Disease Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Lung Disease Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Lung Disease Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 48. GSK Company Details
Table 49. GSK Business Overview
Table 50. GSK Lung Disease Therapeutics Product
Table 51. GSK Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 52. GSK Recent Development
Table 53. AstraZeneca Company Details
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Lung Disease Therapeutics Product
Table 56. AstraZeneca Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 57. AstraZeneca Recent Development
Table 58. Boehringer Ingelheim Company Details
Table 59. Boehringer Ingelheim Business Overview
Table 60. Boehringer Ingelheim Lung Disease Therapeutics Product
Table 61. Boehringer Ingelheim Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 62. Boehringer Ingelheim Recent Development
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Lung Disease Therapeutics Product
Table 66. Novartis Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. Mylan Company Details
Table 69. Mylan Business Overview
Table 70. Mylan Lung Disease Therapeutics Product
Table 71. Mylan Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 72. Mylan Recent Development
Table 73. Vertex Pharmaceuticals Company Details
Table 74. Vertex Pharmaceuticals Business Overview
Table 75. Vertex Pharmaceuticals Lung Disease Therapeutics Product
Table 76. Vertex Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 77. Vertex Pharmaceuticals Recent Development
Table 78. F. Hoffman La Roche Company Details
Table 79. F. Hoffman La Roche Business Overview
Table 80. F. Hoffman La Roche Lung Disease Therapeutics Product
Table 81. F. Hoffman La Roche Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 82. F. Hoffman La Roche Recent Development
Table 83. Teva Pharmaceuticals Company Details
Table 84. Teva Pharmaceuticals Business Overview
Table 85. Teva Pharmaceuticals Lung Disease Therapeutics Product
Table 86. Teva Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 87. Teva Pharmaceuticals Recent Development
Table 88. Cipla Company Details
Table 89. Cipla Business Overview
Table 90. Cipla Lung Disease Therapeutics Product
Table 91. Cipla Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 92. Cipla Recent Development
Table 93. Fibrogen Company Details
Table 94. Fibrogen Business Overview
Table 95. Fibrogen Lung Disease Therapeutics Product
Table 96. Fibrogen Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 97. Fibrogen Recent Development
Table 98. Liminal Biosciences Company Details
Table 99. Liminal Biosciences Business Overview
Table 100. Liminal Biosciences Lung Disease Therapeutics Product
Table 101. Liminal Biosciences Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 102. Liminal Biosciences Recent Development
Table 103. PharmAkea Therapeutics Company Details
Table 104. PharmAkea Therapeutics Business Overview
Table 105. PharmAkea Therapeutics Lung Disease Therapeutics Product
Table 106. PharmAkea Therapeutics Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 107. PharmAkea Therapeutics Recent Development
Table 108. IQVIA Company Details
Table 109. IQVIA Business Overview
Table 110. IQVIA Lung Disease Therapeutics Product
Table 111. IQVIA Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 112. IQVIA Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Lung Disease Therapeutics Picture
Figure 2. Global Lung Disease Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Lung Disease Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Asthma Features
Figure 5. Chronic Obstructive Pulmonary Disease (COPD) Features
Figure 6. Lung Cancer Features
Figure 7. Other Lung Diseases Features
Figure 8. Global Lung Disease Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Lung Disease Therapeutics Market Share by Application: 2024 VS 2031
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. Lung Disease Therapeutics Report Years Considered
Figure 14. Global Lung Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Lung Disease Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Lung Disease Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Lung Disease Therapeutics Market Share by Players in 2024
Figure 18. Global Top Lung Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Disease Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Lung Disease Therapeutics Revenue in 2024
Figure 20. North America Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Lung Disease Therapeutics Market Share by Region (2020-2031)
Figure 34. China Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. GSK Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 50. AstraZeneca Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 53. Mylan Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 54. Vertex Pharmaceuticals Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 55. F. Hoffman La Roche Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 56. Teva Pharmaceuticals Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 57. Cipla Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 58. Fibrogen Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 59. Liminal Biosciences Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 60. PharmAkea Therapeutics Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 61. IQVIA Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Lung Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Asthma
Table 3. Key Players of Chronic Obstructive Pulmonary Disease (COPD)
Table 4. Key Players of Lung Cancer
Table 5. Key Players of Other Lung Diseases
Table 6. Global Lung Disease Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Lung Disease Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Lung Disease Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Lung Disease Therapeutics Market Share by Region (2020-2025)
Table 10. Global Lung Disease Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Lung Disease Therapeutics Market Share by Region (2026-2031)
Table 12. Lung Disease Therapeutics Market Trends
Table 13. Lung Disease Therapeutics Market Drivers
Table 14. Lung Disease Therapeutics Market Challenges
Table 15. Lung Disease Therapeutics Market Restraints
Table 16. Global Lung Disease Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Lung Disease Therapeutics Market Share by Players (2020-2025)
Table 18. Global Top Lung Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Disease Therapeutics as of 2024)
Table 19. Ranking of Global Top Lung Disease Therapeutics Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Lung Disease Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Lung Disease Therapeutics, Headquarters and Area Served
Table 22. Global Key Players of Lung Disease Therapeutics, Product and Application
Table 23. Global Key Players of Lung Disease Therapeutics, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lung Disease Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Lung Disease Therapeutics Revenue Market Share by Type (2020-2025)
Table 27. Global Lung Disease Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Lung Disease Therapeutics Revenue Market Share by Type (2026-2031)
Table 29. Global Lung Disease Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Lung Disease Therapeutics Revenue Market Share by Application (2020-2025)
Table 31. Global Lung Disease Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Lung Disease Therapeutics Revenue Market Share by Application (2026-2031)
Table 33. North America Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Lung Disease Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Lung Disease Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Lung Disease Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Lung Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Lung Disease Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Lung Disease Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 48. GSK Company Details
Table 49. GSK Business Overview
Table 50. GSK Lung Disease Therapeutics Product
Table 51. GSK Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 52. GSK Recent Development
Table 53. AstraZeneca Company Details
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Lung Disease Therapeutics Product
Table 56. AstraZeneca Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 57. AstraZeneca Recent Development
Table 58. Boehringer Ingelheim Company Details
Table 59. Boehringer Ingelheim Business Overview
Table 60. Boehringer Ingelheim Lung Disease Therapeutics Product
Table 61. Boehringer Ingelheim Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 62. Boehringer Ingelheim Recent Development
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Lung Disease Therapeutics Product
Table 66. Novartis Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. Mylan Company Details
Table 69. Mylan Business Overview
Table 70. Mylan Lung Disease Therapeutics Product
Table 71. Mylan Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 72. Mylan Recent Development
Table 73. Vertex Pharmaceuticals Company Details
Table 74. Vertex Pharmaceuticals Business Overview
Table 75. Vertex Pharmaceuticals Lung Disease Therapeutics Product
Table 76. Vertex Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 77. Vertex Pharmaceuticals Recent Development
Table 78. F. Hoffman La Roche Company Details
Table 79. F. Hoffman La Roche Business Overview
Table 80. F. Hoffman La Roche Lung Disease Therapeutics Product
Table 81. F. Hoffman La Roche Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 82. F. Hoffman La Roche Recent Development
Table 83. Teva Pharmaceuticals Company Details
Table 84. Teva Pharmaceuticals Business Overview
Table 85. Teva Pharmaceuticals Lung Disease Therapeutics Product
Table 86. Teva Pharmaceuticals Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 87. Teva Pharmaceuticals Recent Development
Table 88. Cipla Company Details
Table 89. Cipla Business Overview
Table 90. Cipla Lung Disease Therapeutics Product
Table 91. Cipla Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 92. Cipla Recent Development
Table 93. Fibrogen Company Details
Table 94. Fibrogen Business Overview
Table 95. Fibrogen Lung Disease Therapeutics Product
Table 96. Fibrogen Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 97. Fibrogen Recent Development
Table 98. Liminal Biosciences Company Details
Table 99. Liminal Biosciences Business Overview
Table 100. Liminal Biosciences Lung Disease Therapeutics Product
Table 101. Liminal Biosciences Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 102. Liminal Biosciences Recent Development
Table 103. PharmAkea Therapeutics Company Details
Table 104. PharmAkea Therapeutics Business Overview
Table 105. PharmAkea Therapeutics Lung Disease Therapeutics Product
Table 106. PharmAkea Therapeutics Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 107. PharmAkea Therapeutics Recent Development
Table 108. IQVIA Company Details
Table 109. IQVIA Business Overview
Table 110. IQVIA Lung Disease Therapeutics Product
Table 111. IQVIA Revenue in Lung Disease Therapeutics Business (2020-2025) & (US$ Million)
Table 112. IQVIA Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Lung Disease Therapeutics Picture
Figure 2. Global Lung Disease Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Lung Disease Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Asthma Features
Figure 5. Chronic Obstructive Pulmonary Disease (COPD) Features
Figure 6. Lung Cancer Features
Figure 7. Other Lung Diseases Features
Figure 8. Global Lung Disease Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Lung Disease Therapeutics Market Share by Application: 2024 VS 2031
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. Lung Disease Therapeutics Report Years Considered
Figure 14. Global Lung Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Lung Disease Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Lung Disease Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Lung Disease Therapeutics Market Share by Players in 2024
Figure 18. Global Top Lung Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Disease Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Lung Disease Therapeutics Revenue in 2024
Figure 20. North America Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Lung Disease Therapeutics Market Share by Region (2020-2031)
Figure 34. China Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Lung Disease Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Lung Disease Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. GSK Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 50. AstraZeneca Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 53. Mylan Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 54. Vertex Pharmaceuticals Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 55. F. Hoffman La Roche Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 56. Teva Pharmaceuticals Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 57. Cipla Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 58. Fibrogen Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 59. Liminal Biosciences Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 60. PharmAkea Therapeutics Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 61. IQVIA Revenue Growth Rate in Lung Disease Therapeutics Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232